Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 10/2016

01-10-2016

HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD)

Auteurs: N. E. Carlozzi, S. G. Schilling, J.-S. Lai, J. S. Paulsen, E. A. Hahn, J. S. Perlmutter, C. A. Ross, N. R. Downing, A. L. Kratz, M. K. McCormack, M. A. Nance, K. A. Quaid, J. C. Stout, R. C. Gershon, R. E. Ready, J. A. Miner, S. K. Barton, S. L. Perlman, S. M. Rao, S. Frank, I. Shoulson, H. Marin, M. D. Geschwind, P. Dayalu, S. M. Goodnight, D. Cella

Gepubliceerd in: Quality of Life Research | Uitgave 10/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

Huntington disease (HD) is a chronic, debilitating genetic disease that affects physical, emotional, cognitive, and social health. Existing patient-reported outcomes (PROs) of health-related quality of life (HRQOL) used in HD are neither comprehensive, nor do they adequately account for clinically meaningful changes in function. While new PROs examining HRQOL (i.e., Neuro-QoL—Quality of Life in Neurological Disorders and PROMIS—Patient-Reported Outcomes Measurement Information System) offer solutions to many of these shortcomings, they do not include HD-specific content, nor have they been validated in HD. HDQLIFE addresses this by validating 12 PROMIS/Neuro-QoL domains in individuals with HD and by using established PROMIS methodology to develop new, HD-specific content.

Methods

New item pools were developed using cognitive debriefing with individuals with HD, and expert, literacy, and translatability reviews. Existing item banks and new item pools were field tested in 536 individuals with prodromal, early-, or late-stage HD.

Results

Moderate to strong relationships between Neuro-QoL/PROMIS measures and generic self-report measures of HRQOL, and moderate relationships between Neuro-QoL/PROMIS and clinician-rated measures of similar constructs supported the validity of Neuro-QoL/PROMIS in individuals with HD. Exploratory and confirmatory factor analysis, item response theory, and differential item functioning analyses were utilized to develop new item banks for Chorea, Speech Difficulties, Swallowing Difficulties, and Concern with Death and Dying, with corresponding six-item short forms. A four-item short form was developed for Meaning and Purpose.

Conclusions

HDQLIFE encompasses both validated Neuro-QoL/PROMIS measures, as well as five new scales in order to provide a comprehensive assessment of HRQOL in HD.
vorige artikel The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea
volgende artikel The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols
Literatuur
1.
The Huntington’s Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72, 971–983.CrossRef
2.
Ross, C. A., et al. (2014). Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol, 10(4), 204–216.PubMedCrossRef
3.
Squitieri, F., et al. (2015). Epidemiology of Huntington disease: First post-HTT gene analysis of prevalence in Italy. Clinical Genetics, 89, 367–370.PubMedCrossRef
4.
Evans, S. J. W., et al. (2013). Prevalence of adult Huntington’s disease in the UK based on diagnoses recorded in general practice records. Journal of Neurology, Neurosurgery and Psychiatry, 84(10), 1156–1160.PubMedPubMedCentralCrossRef
5.
Paulsen, J. S. (2010). Early detection of huntington disease. Future Neurology, 5(1), 85–104.CrossRef
6.
Ross, C. A., et al. (1997). Huntington disease and the related disorder, dentatorubral–pallidoluysian atrophy (DRPLA). Medicine (Baltimore), 76(5), 305–338.CrossRef
7.
Cella, D. F. (1995). Measuring quality of life in palliative care. Seminars in Oncology, 22(2 Suppl 3), 73–81.PubMed
8.
World Health Organization, W. (1946). Preamble to the constitution of the World Health Organization as adopted by the International Health Conference. In International health conference, New York.
9.
Campbell, A. J., Converse, P. E., & Rodgers, W. L. (1976). The quality of American life: Perceptions, evaluations, and satisfactions. New York: Russell Sage Foundation.
10.
Patrick, D. L., & Erikson, P. (1988). What constitutes quality of life? Concepts and dimensions. Clinical Nutrition, 7(2), 53–63.
11.
Jankovic, J., & Roos, R. A. (2014). Chorea associated with Huntington’s disease: To treat or not to treat? Movement Disorders, 29(11), 1414–1418.PubMedCrossRef
12.
Peavy, G. M., et al. (2010). Cognitive and functional decline in Huntington’s disease: Dementia criteria revisited. Movement Disorders, 25(9), 1163–1169.PubMedPubMedCentralCrossRef
13.
14.
15.
Tibben, A., et al. (1993). Presymptomatic DNA-testing for Huntington disease—Pretest attitudes and expectations of applicants and their partners in the Dutch program. American Journal of Medical Genetics, 48(1), 10–16.PubMedCrossRef
16.
Hocaoglu, M. B., Gaffan, E. A., & Ho, A. K. (2012). The Huntington’s disease health-related Quality of Life questionnaire (HDQoL): A disease-specific measure of health-related quality of life. Clinical Genetics, 81(2), 117–122.PubMedPubMedCentralCrossRef
17.
Paulsen, J. S., et al. (2013). A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Progress in Neurobiology, 110, 2–28.PubMedCrossRef
18.
Cella, D., et al. (2011). The neurology quality of life measurement (Neuro-QOL) initiative. Archives of Physical Medicine and Rehabilitation, 92(Suppl 1), S28–S36.PubMedPubMedCentralCrossRef
19.
Gershon, R. C., et al. (2012). Neuro-QOL: Quality of life item banks for adults with neurological disorders: Item development and calibrations based upon clinical and general population testing. Quality of Life Research, 21(3), 475–486.PubMedCrossRef
20.
Cella, D., et al. (2010). The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested in its first wave of adult self-reported health outcome item banks: 2005–2008. Journal of Clinical Epidemiology, 63, 1179–1194.PubMedPubMedCentralCrossRef
21.
van der Linden, W. J., & Hambleton, R. K. (1997). Handbook of modern item response theory. New York: Springer.CrossRef
22.
23.
Choppin, B. (1981). Educational measurement and the item bank model. In C. Lacey & D. Lawton (Eds.), Issues in evaluation and accountability (pp. 204–221). London: Methuen.
24.
Nance, M. A. (2007). Comprehensive care in Huntington’s disease: A physician’s perspective. Brain Research Bulletin, 72(2–3), 175–178.PubMedCrossRef
25.
Lai, J. S., et al. (2011). How item banks and its applications can influence measurement practice in rehabilitation medicine: A PROMIS fatigue item bank example. Archives of Physical Medicine and Rehabilitation, 92(Supp 1), S20–S27.PubMedPubMedCentralCrossRef
26.
Carlozzi, N. E., et al. (2016). New measures to capture end of life concerns in Huntington disease: Meaning and purpose and concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Quality of Life Research. doi:10.​1007/​s11136-016-1354-y.
27.
Carlozzi, N. E., et al. (2016). The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Quality of Life Research.. doi:10.​1007/​s11136-016-1307-5.
28.
Carlozzi, N. E., et al. (2016). HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Quality of Life Research. doi:10.​1007/​s11136-016-1273-y.
29.
30.
Carlozzi, N. E., & Tulsky, D. S. (2013). Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. Journal of Health Psychology, 18(2), 212–225.PubMedCrossRef
31.
Kisala, P., & Tulsky, D. (2010). Opportunities for CAT applications in medical rehabilitation: Development of targeted item banks. Journal of Applied Measurement, 11(3), 315–330.PubMed
32.
Tourangeau, R. (1984). Cognitive sciences and survey methods. In T. Jabine, et al. (Eds.), Cognitive Aspects of survey methodology: Building a bridge between disciplines (pp. 73–100). Washington, DC: National Academy Press.
33.
MetaMetrics. (1995). The LEXILE framework for reading. Durham, NC: MetaMetrics Inc.
34.
Shoulson, I., & Fahn, S. (1979). Huntington disease—Clinical care and evaluation. Neurology, 29(1), 1–3.PubMedCrossRef
35.
Hanauer, D. A., et al. (2015). Supporting information retrieval from electronic health records: A report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). Journal of Biomedical Informatics, 55, 290–300.PubMedPubMedCentralCrossRef
36.
Paulsen, J. S., et al. (2006). Preparing for preventive clinical trials: The predict-HD study. Archives of Neurology, 63(6), 883–890.PubMedCrossRef
37.
Paulsen, J. S., et al. (2008). Detection of Huntington’s disease decades before diagnosis: The Predict-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 79(8), 874–880.PubMedCrossRef
38.
Paulsen, J. S., et al. (2014). Clinical and biomarker changes in premanifest huntington disease show trial feasibility: A decade of the PREDICT-HD study. Frontiers in Aging Neuroscience, 6, 78.PubMedPubMedCentralCrossRef
39.
Huntington Study Group. (1996). Unified Huntington’s Disease Rating Scale: Reliability and consistency. Movement Disorders, 11(2), 136–142.CrossRef
40.
Hogarth, P., et al. (2005). Interrater agreement in the assessment of motor manifestations of Huntington’s disease. Movement Disorders, 20(3), 293–297.PubMedCrossRef
41.
Huntington Study Group. (2006). Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology, 66(3), 366–372.CrossRef
42.
Siesling, S., et al. (1998). Unified Huntington’s disease rating scale: A follow up. Movement Disorders, 13(6), 915–919.PubMedCrossRef
43.
Tabrizi, S. J., et al. (2011). Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurology, 10(1), 31–42.PubMedCrossRef
44.
45.
Carlozzi, N. E., et al. (2014). Understanding the outcomes measures used in huntington disease pharmacological trials: A systematic review. Journal of Huntington’s Disease, 3(3), 233–252.PubMedPubMedCentral
46.
47.
Smith, A. (1982). Symbol digit modalities test: Manual. Los Angeles: Western Psychological Services.
48.
Stroop, J. R. (1992). Studies of interference in serial verbal reactions (Reprinted from Journal Experimental-Psychology, Vol. 18, pp. 643–662, 1935). Journal of Experimental Psychology-General, 121(1): 15–23.
49.
Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18, 643–662.CrossRef
50.
Craufurd, D., Thompson, J. C., & Snowden, J. S. (2001). Behavioral changes in Huntington disease. Neuropsychiatry, Neuropsychology, & Behavioral Neurology, 14(4), 219–226.
51.
52.
Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337–343.PubMedCrossRef
53.
Lord, F. M. (1980). Applications of item response theory to practical testing problems. Hillside, NJ: Erlbaum.
54.
De Ayala, R. J. (2009). The theory and practice of item response theory. New York: The Guilford Press.
55.
56.
Muthén, L. K., & Muthén, B. O. (2011). Mplus User’s Guide. Los Angeles, CA: Muthén & Muthén.
57.
McDonald, R. P. (1999). Test theory: A unified treatment. Mahwah, NJ: Lawrence Erlbaum Associates Inc.
58.
Cook, K. F., Kallen, M. A., & Amtmann, D. (2009). Having a fit: Impact of number of items and distribution of data on traditional criteria for assessing IRT’s unidimensionality assumption. Quality of Life Research, 18(4), 447–460.PubMedPubMedCentralCrossRef
59.
Reise, S. P., Morizot, J., & Hays, R. D. (2007). The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Quality of Life Research, 16(Suppl 1), 19–31.PubMedCrossRef
60.
Samejima, F., van der Liden, W. J., & Hambleton, R. (1996). The graded response model. In W. J. van der Liden (Ed.), Handbook of modern item response theory (pp. 85–100). NY: Springer.
61.
Cai, L., Thissen, D., & du Toit, S. H. C. (2011). IRTPRO for windows [Computer software]. 2011, Lincolnwood, IL: Scientific Software International.
62.
R Core Team. (2014). R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.
63.
Choi, S. W., Gibbons, L. E., & Crane, P. K. (2011). Lordif: An R package for detecting differential item functioning using iterative hybrid ordinal logistic regression/item response theory and monte carlo simulations. Journal of Statistical Software, 39(8), 1–30.PubMedPubMedCentralCrossRef
64.
Ustun, T. B., et al. (2010). Developing the World Health Organization Disability Assessment Schedule 2.0. Bulletin of the World Health Organization, 88(11), 815–823.PubMedPubMedCentralCrossRef
65.
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). New York: Academic Press.
66.
Samejima, F. (1969). Estimation of latent ability using a response pattern of graded scores (Psychometric Monograph No. 17). Richmond, VA: Psychometric Society.
67.
Bryant, F. B., & Yarnold, P. R. (1995). Principal components analysis and exploratory and confirmatory factor analysis. In L. G. Grimm & R. R. Yarnold (Eds.), Reading and understanding multivariate statistics (pp. 99–136). Washington, DC: American Psychological Association.
68.
Everitt, B. S. (1975). Multivariate analysis: The need for data, and other problems. British Journal of Psychiatry, 126, 237–240.PubMedCrossRef
69.
Gorsuch, R. L., & Analysis, Factor. (1983). Hillsdale. NJ: Lawrence Erlbaum Associates.
70.
Clauser, B. E., & Hambleton, R. K. (1994). Review of differential item functioning, P. W. Holland, H. Wainer. Journal of Educational Measurement, 31(1), 88–92.CrossRef
71.
Anastasi, A., & Urbina, S. (1997). Psychological testing (7th ed.). Upper Saddle River, NJ: Prentice Hall.
72.
Tabrizi, S. J., et al. (2012). Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurology, 11(1), 42–53.PubMedCrossRef
73.
74.
Smith, K. M., & Dahodwala, N. (2014). Sex differences in Parkinson’s disease and other movement disorders. Experimental Neurology, 259, 44–56.PubMedCrossRef
75.
Tabrizi, S. J., et al. (2009). Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurology, 8(9), 791–801.PubMedPubMedCentralCrossRef
76.
Paulsen, J. S., et al. (2014). Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD study. Front Aging Neurosci, 6, 78.PubMedPubMedCentralCrossRef
77.
Dunn, K. M., et al. (2004). Patterns of consent in epidemiologic research: Evidence from over 25,000 responders. American Journal of Epidemiology, 159(11), 1087–1094.PubMedCrossRef
78.
Burg, J. A., Allred, S. L., & Sapp, J. H, 2nd. (1997). The potential for bias due to attrition in the National Exposure Registry: An examination of reasons for nonresponse, nonrespondent characteristics, and the response rate. Toxicology and Industrial Health, 13(1), 1–13.PubMed
79.
Eagan, T. M., et al. (2002). Nonresponse in a community cohort study: Predictors and consequences for exposure-disease associations. Journal of Clinical Epidemiology, 55(8), 775–781.PubMedCrossRef
80.
Haga, S. B., et al. (2013). Public knowledge of and attitudes toward genetics and genetic testing. Genetic Testing and Molecular Biomarkers, 17(4), 327–335.PubMedPubMedCentralCrossRef
81.
Roberts, J. S., et al. (2004). Who seeks genetic susceptibility testing for Alzheimer’s disease? Findings from a multisite, randomized clinical trial. Genetics in Medicine, 6(4), 197–203.PubMedCrossRef
82.
Huntington Study Group, P.I., et al. (2016). Clinical-genetic associations in the prospective Huntington at Risk Observational Study (PHAROS): Implications for clinical trials. JAMA Neurology, 73(1), 102–110.CrossRef
83.
Pringsheim, T., et al. (2012). The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Movement Disorders, 27(9), 1083–1091.PubMedCrossRef
84.
Folstein, S. E. (1989). Huntington’s disease: A disorder of families. Baltimore: Johns Hopkins University Press.
85.
Hayden, M. R., MacGregor, J. M., & Beighton, P. H. (1980). The prevalence of Huntington’s chorea in South Africa. South African Medical Journal, 58, 193–196.PubMed
86.
Narabayashi, H. (1973). Huntington’s chorea in Japan: Review of the literature. Advances in Neurology, 1, 253–259.
87.
88.
Rutherford, C., et al. (2016). Mode of administration does not cause bias in patient-reported outcome results: A meta-analysis. Quality of Life Research, 25(3), 559–574.PubMedCrossRef
89.
Duff, K., et al. (2010). “Frontal” behaviors before the diagnosis of Huntington’s disease and their relationship to markers of disease progression: Evidence of early lack of awareness. Journal of Neuropsychiatry and Clinical Neurosciences, 22(2), 196–207.PubMedPubMedCentralCrossRef
90.
Bull, M. T., et al. (2014). A pilot study of virtual visits in Huntington disease. Journal of Huntington’s Disease, 3(2), 189–195.PubMed
Metagegevens
Titel
HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD)
Auteurs
N. E. Carlozzi
S. G. Schilling
J.-S. Lai
J. S. Paulsen
E. A. Hahn
J. S. Perlmutter
C. A. Ross
N. R. Downing
A. L. Kratz
M. K. McCormack
M. A. Nance
K. A. Quaid
J. C. Stout
R. C. Gershon
R. E. Ready
J. A. Miner
S. K. Barton
S. L. Perlman
S. M. Rao
S. Frank
I. Shoulson
H. Marin
M. D. Geschwind
P. Dayalu
S. M. Goodnight
D. Cella
Publicatiedatum
01-10-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 10/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-016-1386-3

Andere artikelen Uitgave 10/2016

Quality of Life Research 10/2016 Naar de uitgave

OriginalPaper

New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system)

OriginalPaper

Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy

OriginalPaper

The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea

OriginalPaper

Assessing health-related quality of life in patients with breast cancer: a systematic and standardized comparison of available instruments using the EMPRO tool

OriginalPaper

Eating disorder features and quality of life: Does gender matter?

OriginalPaper

HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties